secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rapport Therapeutics, Inc. (RAPP)
CIK:        0002012593
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001193125-26-099336
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rapport Therapeutics reports FY2025 net loss $111.5M, RAP-219 Phase 2 positive, Phase 3 Q2 2026
--------------------------------------------------------------------------------

- Net loss Q4 2025 $33.8M, full year $111.5M; R&D expenses $94.8M FY2025 vs $60.9M FY2024.
- Cash, equivalents, short-term investments $490.5M at Dec 31, 2025; runway into H2 2029.
- RAP-219 Phase 2a in focal onset seizures met primary endpoints: 77.8% median reduction in clinical seizure frequency.
- Phase 3 program for RAP-219 in FOS accelerated to Q2 2026; open-label safety trial enrolling.
- Entered Tenacia collaboration for Greater China: $20M upfront, up to $308M milestones plus tiered royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2012593/000119312526099336/0001193125-26-099336-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2012593/000119312526099336/rapp-20260310.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-099336

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer